This post is sponsored by DIA.
There are many challenges to overcome to develop and disseminate technology to health care providers and decision-makers. The largest, multidisciplinary life sciences meeting in North America, the DIA 2013 49th Annual Meeting, will give attendees the opportunity to discuss these issues and hear about innovative solutions.
DIA 2013 49th Annual Meeting, to be held in Boston, Mass., from June 23-27, will feature a session titled “Unique Nonprofit-Industry Partnerships to Develop and Disseminate Technology“, under the Innovative Partnering Models and Outsourcing Strategies track.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The session, to be held on June 26 from 8:00 – 9:30 a.m., will present three real-world examples highlighting unique aspects of nonprofit-industry partnerships and how they have helped to break down barriers such as the small scale of a producer, lack of complete patient population data, or unfavorable economics/governance.
The examples include a foundation’s $16 million funding effort to disseminate technology for simulating virtual patient populations; the Merck-Regenstrief Institute partnership for the co-development and dissemination of technology to support real-world evidence-based research and health care innovation; and a university’s direct investment in creating a personalized medicine startup.
The session, chaired by Badri Rengarajan, MD, Medical Director, Archimedes, Inc., will feature presentations from Brian Quinn, PhD, Team Director and Senior Program Officer, Robert Wood Johnson Foundation; Patrick Michael Loerch, PhD, Director, Health Informatics, Merck & Co., Inc.; and Ralph Lin, Global Strategy and Corporate Development Officer, Shin Nippon Biomedical Laboratories, Japan.
The DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science is the largest multidisciplinary event that brings together a global community of professionals at all levels and across all disciplines in the discovery, development, and life cycle management of medical products, all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Returning to Boston, one of the strongest life sciences regions in the United States, this year’s event will feature 250+ sessions over 22 tracks on hot topics from key thought leaders from the life sciences industry.
The meeting provides participants with a valuable opportunity to meet professionals from around the world, share knowledge and experience, network, and build new relationships.
Find out more about DIA 2013 49th Annual Meeting at www.diahome.org/DIA2013.
Register by May 17 to reserve your spot on the Advance Attendee List.
